Ocean Biomedical, Inc. (OCEA)

US — Healthcare Sector
Peers: ENVB  HEPA  ELEV  AVRO  CWBR  ZURA  EFTR 

Automate Your Wheel Strategy on OCEA

With Tiblio's Option Bot, you can configure your own wheel strategy including OCEA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OCEA
  • Rev/Share 0.0
  • Book/Share -3.3597
  • PB -0.0018
  • Debt/Equity -0.1012
  • CurrentRatio 0.0562
  • ROIC 0.1773

 

  • MktCap 1440663.0
  • FreeCF/Share -0.1473
  • PFCF -0.3556
  • PE -0.0069
  • Debt/Assets 5.9102
  • DivYield 0
  • ROE 0.2577

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Ocean Biomedical, Inc. (OCEA)

  • IPO Date 2021-11-08
  • Website http://www.oceanbiomedical.com
  • Industry Biotechnology
  • CEO Dr. Inderjote Kathuria M.B.A., M.D.
  • Employees 7
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.